NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE214820 Query DataSets for GSE214820
Status Public on Oct 05, 2022
Title Baseline Clinical, Hormonal and Molecular Markers Associated with Clinical Response to IL-23 Antagonism in Hidradenitis Suppurativa
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Background: Hidradenitis Suppurativa is a complex inflammatory disease in which predicting therapeutic response remains challenging. Clinical trials of IL-23 antagonism have shown high variability leading to abandonment of various clinical trials. IL-23 is known to interact with sex hormones in. monocytes, dendritic cells, and T cells. Relationships of IL-23 clinical response in HS to hormonal and molecular markers of inflammation has not been previously assessed.
Objectives: To assess whether baseline clinical, hormonal, or molecular markers are associated with clinical response to IL-23 antagonism with Risankizumab in Hidradenitis Suppurativa.
Methods: 26 individuals with Hurley Stage 2/3 disease were administered Risankizumab 150mg Week 0,4,12. Baseline sex hormones and skin biopsies were taken. Clinical response at Week 16 assessed by the HiSCR, and differences between responders and non-responders assessed.
Results: Clinical response to IL-23 antagonism was associated with male gender, elevated total serum testosterone, and decreased levels of FSH. nCounter gene expression identified consistent differential expressed genes to previously published RNAseq datasets. Stratification by clinical responders/non responders identified differentially expressed genes included TRAT1, TPSAB1/2, LTA, IL17A, CXCR1 as well as hormonally responsive genes including PLPP4 and MAPK10. Immunohistochemistry identified elevated numbers of CD11c, IL-17A and IL-17F positive cells compared to non-responders. CD11c+ cells significantly correlated with serum levels of total testosterone and inversely correlated with serum FSH.
 
Overall design Baseline Data, Nanostring nCounter Human Fibrosis V2.0 Panel
 
Contributor(s) Flora A, Frew J
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Oct 04, 2022
Last update date Oct 08, 2022
Contact name John Frew
E-mail(s) John.frew@unsw.edu.au
Organization name Liverpool Hospital
Department Dermatology
Street address Elizabeth St
City Liverpool
ZIP/Postal code 2170
Country Australia
 
Platforms (1)
GPL31258 NanoString nCounter human fibrosis panel [NS_HS_FIBROSIS_V2.0 or V2.1]
Samples (26)
GSM6616276 Patient 1
GSM6616277 Patient 2
GSM6616278 Patient 3
Relations
BioProject PRJNA887125

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE214820_RAW.tar 240.0 Kb (http)(custom) TAR (of RCC)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap